Your browser doesn't support javascript.
loading
Same-day discharge after catheter ablation in patients with atrial fibrillation in a large nationwide administrative claims database.
Field, Michael E; Goldstein, Laura; Corriveau, Kevin; Khanna, Rahul; Fan, Xiaozhou; Gold, Michael R.
Afiliação
  • Field ME; Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
  • Goldstein L; Johnson & Johnson Medical Devices, Franchise Health Economics and Market Access, Irvine, California, USA.
  • Corriveau K; Johnson & Johnson Medical Devices, Franchise Health Economics and Market Access, Irvine, California, USA.
  • Khanna R; Medical Device Epidemiology & Real-World Data Science, Johnson and Johnson, New Brunswick, New Jersey, USA.
  • Fan X; Medical Device Epidemiology & Real-World Data Science, Johnson and Johnson, New Brunswick, New Jersey, USA.
  • Gold MR; Department of Medicine, Medical University of South Carolina, Charleston, South Carolina, USA.
J Cardiovasc Electrophysiol ; 32(9): 2432-2440, 2021 09.
Article em En | MEDLINE | ID: mdl-34324239
ABSTRACT

BACKGROUND:

Catheter ablation (CA) is a common treatment for atrial fibrillation (AF). This study evaluated outcomes of same day discharge (SDD) versus overnight stay (ONS) among AF patients undergoing outpatient CA.

METHODS:

The Optum SES Clinformatics Extended Data Mart database was used to identify patients ≥18 years of age undergoing outpatient CA for AF (2016-2020). Eligible patients were indexed to the date of first CA and classified into SDD and ONS groups based on the length of service. A 13 propensity score matching was used to create comparable SDDONS samples. The primary safety outcome was CA-related complications within 30 days of index procedure. The primary efficacy outcome was AF recurrence within 1 year. Cox proportional hazards models were estimated for outcome comparison.

RESULTS:

In the postmatch 30-day cohort for safety evaluation, there were 6600 patients (1660 [25.2%] SDD; 4940 [74.8%] ONS), with a mean age of 66.6 years. There was no significant difference in the 30-day composite rate of postablation complications (4.7% [78/1660] vs. 3.8% [187/4940]; p = 0.100) and 1-year composite rate of AF recurrence (14.3% [142/996] vs. 14.5% [430/2972]; p = 0.705) between the SDD and ONS groups.

CONCLUSION:

This study demonstrated that SDD following CA to treat patients with AF is safe, with low rates of postablation complications and AF recurrence, which were comparable to rates in patients with an ONS after CA.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Ablação por Cateter Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Aged / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Fibrilação Atrial / Ablação por Cateter Tipo de estudo: Diagnostic_studies / Prognostic_studies Limite: Aged / Humans Idioma: En Ano de publicação: 2021 Tipo de documento: Article